CAP President Donald S. Karcher, MD, FCAP, discusses the LDT court ruling. “We opposed the FDA’s rulemaking because it would threaten patient access to these critically important diagnostic tests,” Dr. Karcher says.
For the full article click here: Next Steps: With LDT Final Rule Now Null, Industry Groups Urge Lab Managers and Pathologists to Advocate for Change